

Join leading experts for:

Keeping pace with the evidence base: Applying the latest findings in mHSPC



Thursday 11th June



10:30 - 11:30am



Queen Suite 5

Meet the faculty:



Dr Henno Martin

Consultant in Clinical Oncology at Cambridge University Hospitals, Consultant Clinical Oncologist at GenesisCare Newmarket, and Inpatient Model of Care Lead for the Cambridge Cancer Research Hospital.

He specialises in the treatment of prostate, bladder and breast cancers, with expertise across radiotherapy, systemic therapy and personalised cancer care. His research focuses on circulating tumour DNA blood tests to guide treatment decisions and reduce the need for invasive monitoring, work recognised through national awards, research funding and international presentations. His wider professional work includes contributions to Royal College of Radiologists projects and national quality review processes.



Dr Vincent Khoo

Consultant in Clinical Oncology at The Royal Marsden, Honorary Consultant at St George's Hospital and Honorary Senior Lecturer at The Institute of Cancer Research, University of London.

He is Lead, Clinical Trials Unit Urology Chelsea at Chelsea Branch of The Royal Marsden Hospital that investigates a comprehensive array of therapies, from stereotactic radiotherapy to image guided intensity modulated and adaptive radiotherapy to systemic therapies such as hormonal, targeted therapies and chemotherapy in Phase I to III Clinical Trials.

ERLEADA® (apalutamide) is indicated:

- in adult men for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC) who are at high risk* of developing metastatic disease
- in adult men for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT)

Medical castration with gonadotropin-releasing hormone analogue (GnRH α) should be continued during ERLEADA® + ADT treatment in patients who have not been surgically castrated.^{1,2}

*High risk is defined as patients with a prostate-specific antigen doubling time of ≤ 10 months.^{1,2}

Adverse events associated with a Janssen/Johnson & Johnson company product should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Johnson & Johnson's Drug Safety Department on 01494 567447 or at dsafety@its.jnj.com.

Abbreviations: ADT, androgen deprivation therapy; mHSPC, metastatic hormone sensitive prostate cancer; nmCRPC, non metastatic castration resistant prostate cancer; RCTs, randomised controlled trials; RWE, real world evidence

References:

1. ERLEADA® (apalutamide). 240 mg Summary of Product Characteristics. United Kingdom.
2. ERLEADA® (apalutamide). 60 mg Summary of Product Characteristics. United Kingdom.

Scan or click here for prescribing information for ERLEADA®

